Sparsentan_DF3, Sparsentan_DF2, Sparsentan_DF4
RTRX-RE021-201
Phase 2 small_molecule active
Quick answer
Sparsentan_DF3, Sparsentan_DF2, Sparsentan_DF4 for Proteinuric glomerular diseases including: •Focal segmental glomerulosclerosis (FSGS) •Minimal change disease (MCD) •Immunoglobulin A nephropathy (IgAN) •Immunoglobulin A vasculitis (IgAV) •Alport syndrome (AS) is a Phase 2 program (small_molecule) at Travere Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Travere Therapeutics
- Indication
- Proteinuric glomerular diseases including: •Focal segmental glomerulosclerosis (FSGS) •Minimal change disease (MCD) •Immunoglobulin A nephropathy (IgAN) •Immunoglobulin A vasculitis (IgAV) •Alport syndrome (AS)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active